ISSCR Annual Meeting 2026
The program showcases the latest advances across stem cell biology, disease modeling, clinical translation, engineering biology, developmental biology, and regenerative medicine, providing a comprehensive view of emerging science and therapeutic applications. ISSCR 2026 features plenary lectures from world-renowned scientists, award presentations recognizing leaders across career stages, concurrent scientific tracks, poster sessions, networking forums, career development panels, and innovation showcases highlighting new technologies and tools.
The meeting is designed to foster collaboration across academia, industry, and healthcare while accelerating the translation of stem cell discoveries into clinical applications. For companies working in cell and gene therapy, regenerative medicine, research tools, manufacturing, or translational medicine, ISSCR offers a valuable opportunity to engage with key opinion leaders, discover emerging trends, and build strategic partnerships within the global stem cell ecosystem.
Date: Jul 08 – 11, 2026
Location: Palais des congrès de Montréal
Montreal, Quebec, Canada
JOIN US!
Our iPSC services cover off-the-shelf offerings, custom banking, differentiated cells and iPSC manipulation services for cell therapy programs. Our cell lines offer features such as HLA-homozygosity or favorable blood groups, with full regulatory documentation and support, to shorten the runway into clinical studies. Come meet our team to learn more about our comprehensive iPSC offerings.
Complete the form to schedule a meeting with our experts!
SPEAKING ENGAGEMENTS!
Panel Discussion
Date/Time: July 8, 2:15 PM – 3:45 PM ((UTC-04:00) Eastern Time (US & Canada))
Title: Accelerating pathways from iPSC lines to patient cure: Challenges, solutions, and value of global partnerships
Session Chair: Frederic Cedrone, Vice President Corporate Innovation, 91Ï㽶ÊÓƵ
Panelists:
Ricardo Baptista, Chief Technology Officer, SmartCella
Bo Wiinberg, Chief Business Development Officer, Novo Nordisk Foundation Cellerator
Brock Reeve, Chief Executive Office, Eos BioInnovation
Gregory Russotti, Chief Technology and Manufacturing Officer, Century Therapeutics
Massimiliano Paganelli, Chief Executive Officer, Morphocell Technologies
ABOUT CATALENT
91Ï㽶ÊÓƵ. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 91Ï㽶ÊÓƵ helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 91Ï㽶ÊÓƵ provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 91Ï㽶ÊÓƵ tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 91Ï㽶ÊÓƵ supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
